Cargando…
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies
Conventional approaches to isolate and characterize nanobodies are laborious. We combine phage display, multivariate enrichment, next-generation sequencing, and a streamlined screening strategy to identify numerous anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nanobodies. We char...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956255/ https://www.ncbi.nlm.nih.gov/pubmed/35333580 http://dx.doi.org/10.1126/sciadv.abm0220 |
_version_ | 1784676525655719936 |
---|---|
author | Hanke, Leo Sheward, Daniel J. Pankow, Alec Vidakovics, Laura Perez Karl, Vivien Kim, Changil Urgard, Egon Smith, Natalie L. Astorga-Wells, Juan Ekström, Simon Coquet, Jonathan M. McInerney, Gerald M. Murrell, Ben |
author_facet | Hanke, Leo Sheward, Daniel J. Pankow, Alec Vidakovics, Laura Perez Karl, Vivien Kim, Changil Urgard, Egon Smith, Natalie L. Astorga-Wells, Juan Ekström, Simon Coquet, Jonathan M. McInerney, Gerald M. Murrell, Ben |
author_sort | Hanke, Leo |
collection | PubMed |
description | Conventional approaches to isolate and characterize nanobodies are laborious. We combine phage display, multivariate enrichment, next-generation sequencing, and a streamlined screening strategy to identify numerous anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nanobodies. We characterize their potency and specificity using neutralization assays and hydrogen/deuterium exchange mass spectrometry (HDX-MS). The most potent nanobodies bind to the receptor binding motif of the receptor binding domain (RBD), and we identify two exceptionally potent members of this category (with monomeric half-maximal inhibitory concentrations around 13 and 16 ng/ml). Other nanobodies bind to a more conserved epitope on the side of the RBD and are able to potently neutralize the SARS-CoV-2 founder virus (42 ng/ml), the Beta variant (B.1.351/501Y.V2) (35 ng/ml), and also cross-neutralize the more distantly related SARS-CoV-1 (0.46 μg/ml). The approach presented here is well suited for the screening of phage libraries to identify functional nanobodies for various biomedical and biochemical applications. |
format | Online Article Text |
id | pubmed-8956255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-89562552022-04-04 Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies Hanke, Leo Sheward, Daniel J. Pankow, Alec Vidakovics, Laura Perez Karl, Vivien Kim, Changil Urgard, Egon Smith, Natalie L. Astorga-Wells, Juan Ekström, Simon Coquet, Jonathan M. McInerney, Gerald M. Murrell, Ben Sci Adv Biomedicine and Life Sciences Conventional approaches to isolate and characterize nanobodies are laborious. We combine phage display, multivariate enrichment, next-generation sequencing, and a streamlined screening strategy to identify numerous anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nanobodies. We characterize their potency and specificity using neutralization assays and hydrogen/deuterium exchange mass spectrometry (HDX-MS). The most potent nanobodies bind to the receptor binding motif of the receptor binding domain (RBD), and we identify two exceptionally potent members of this category (with monomeric half-maximal inhibitory concentrations around 13 and 16 ng/ml). Other nanobodies bind to a more conserved epitope on the side of the RBD and are able to potently neutralize the SARS-CoV-2 founder virus (42 ng/ml), the Beta variant (B.1.351/501Y.V2) (35 ng/ml), and also cross-neutralize the more distantly related SARS-CoV-1 (0.46 μg/ml). The approach presented here is well suited for the screening of phage libraries to identify functional nanobodies for various biomedical and biochemical applications. American Association for the Advancement of Science 2022-03-25 /pmc/articles/PMC8956255/ /pubmed/35333580 http://dx.doi.org/10.1126/sciadv.abm0220 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Hanke, Leo Sheward, Daniel J. Pankow, Alec Vidakovics, Laura Perez Karl, Vivien Kim, Changil Urgard, Egon Smith, Natalie L. Astorga-Wells, Juan Ekström, Simon Coquet, Jonathan M. McInerney, Gerald M. Murrell, Ben Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies |
title | Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies |
title_full | Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies |
title_fullStr | Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies |
title_full_unstemmed | Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies |
title_short | Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies |
title_sort | multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing sars-cov-2 nanobodies |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956255/ https://www.ncbi.nlm.nih.gov/pubmed/35333580 http://dx.doi.org/10.1126/sciadv.abm0220 |
work_keys_str_mv | AT hankeleo multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT shewarddanielj multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT pankowalec multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT vidakovicslauraperez multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT karlvivien multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT kimchangil multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT urgardegon multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT smithnataliel multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT astorgawellsjuan multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT ekstromsimon multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT coquetjonathanm multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT mcinerneygeraldm multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies AT murrellben multivariateminingofanalpacaimmunerepertoireidentifiespotentcrossneutralizingsarscov2nanobodies |